Skyhawk Therapeutics Announces Positive Final Phase 1/2 Results for Huntington's Disease Treatment SKY-0515

Skyhawk Therapeutics has released final fifteen-month results from its Phase 1/2 clinical trial of SKY-0515, an investigational oral treatment for Huntington's disease. The study showed that patients treated with SKY-0515 improved on the Composite Unified Huntington's Disease Rating Scale (cUHDRS) by an average of 0.94 points, while an untreated comparison group declined by 0.65 points. The difference favoring SKY-0515 was statistically significant across all four cUHDRS components. The drug also demonstrated consistent average reductions in mutant huntingtin protein (mHTT) of over 60% at the 9 mg dose.